• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bloomberg Expands Global Equity Offering with Australia Domestic Equity Indices

    4/28/26 5:30:00 PM ET
    $A
    $AD
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Telecommunications Equipment
    Telecommunications
    Get the next $A alert in real time by email

    New indices deliver transparent, comprehensive access to Australian equities for benchmarking and investment applications

    NEW YORK and SYDNEY, April 28, 2026 /PRNewswire/ -- Bloomberg today announced the launch of the new Bloomberg Australia Domestic Equity Indices. The indices are designed to provide broad and investable exposure to Australian equities for benchmarking, asset allocation, and creation of financial products for both institutional and retail investors.

    Bloomberg (PRNewsfoto/Bloomberg)

    "The launch of our Australia Domestic Equity Indices represents a natural evolution of our offering, building on a strong global equity foundation designed to provide a comprehensive representation of the market through the lens of the domestic investors, backed by same high standards of data quality and analytics," said Ji Zhuang, Head of APAC for Bloomberg Index Services Limited. "This expansion marks a strategic milestone in our continued commitment to Australia where we have long supported the region's investment community, being a leading fixed income benchmark provider with our flagship AusBond indices."

    The Bloomberg Australia Domestic Equity Indices are built using a transparent, rules-based methodology designed to provide a comprehensive representation of the Australian equity universe. The launch includes a total of 36 new indices, spanning flagship benchmarks and a range of 'Select' indices that provide targeted exposure to the Australian equities market. This includes frequently requested segments, such as:

    • Bloomberg Australia Domestic 50 Index (NYSE:AD)
    • Bloomberg Australia Domestic 100 Index (NYSE:AD)
    • Bloomberg Australia Domestic 200 Index (NYSE:AD)
    • Bloomberg Australia Domestic 300 Index (NYSE:AD)
    • Bloomberg Australia Domestic Mid 50 Index (BLOOMBERG TICKER:ADMC)
    • Bloomberg Australia Domestic Small 200 Index (XSTC:ADS)

    To reflect the needs of domestic investors, Bloomberg also offers index return variants that incorporate the impact of dividend franking credits, such as:

    • Bloomberg Australia Domestic 200 Grossed Up Franked Return Index (NYSE:A)
    • Bloomberg Australia Domestic 200 Superannuation Franked Return Index (NYSE:A)
    • Bloomberg Australia Domestic 300 Grossed Up Franked Return Index (NYSE:A)
    • Bloomberg Australia Domestic 300 Superannuation Franked Return Index (NYSE:A)

    Together, these indices are designed to reflect the structure and dynamics of Australia's domestic equity market. Key features include:

    • Flexible and Customizable Design: Indices can be tailored to meet specific investment objectives, including sector, size, factor, and sustainability considerations.
    • Deep Integration with the Bloomberg Terminal: Bloomberg indices are fully integrated into the Bloomberg Terminal, enabling users to analyze constituents and build portfolios within a unified workflow. Clients can access index data down to the constituent level, enabling advanced analytics, portfolio construction, and performance evaluation using tools such as {MEMB <GO>} and {PORT <GO>}.

    Bloomberg Equity Indices are a comprehensive set of global families covering over 99+% of the eligible free float market cap more than 40 countries. Bloomberg Equity Indices are available in global, regional, country, and sector exposures, in various currencies and returns (price/total/net). The offering also includes traditional growth and value style indices, factor index strategies, thematics, ESG customization and additional bespoke capabilities for benchmarking, asset allocation, and product creation. Flagship equity benchmarks include the World, Developed Markets and Emerging Markets Large & Mid Cap Indices, as well as the Bloomberg 500 (B500) Index.

    Bloomberg clients can access the new indices on the Bloomberg Terminal at {IN <GO>}, Bloomberg's index search and discovery function on the Bloomberg Terminal. All research and index methodology documents are available on the Bloomberg Indices Documentation page.  

    About Bloomberg Index Services Limited

    Bloomberg's index team has a proven track record in creating industry-leading and bespoke indices across asset classes, including their flagship fixed income, commodity and equity indices. BISL takes an innovative approach to delivering strategic benchmarks that help market participants address their evolving investment needs. The indices, which are seamlessly integrated with other Bloomberg solutions, draw on a comprehensive range of trusted data and reliable technology for calculations, analytics and workflow automation, along with distribution capabilities that can help amplify the visibility of our customers' products.

    About Bloomberg

    Bloomberg is a global leader in business and financial information, delivering trusted data, news, and insights that bring transparency, efficiency, and fairness to markets. The company helps connect influential communities across the global financial ecosystem via reliable technology solutions that enable our customers to make more informed decisions and foster better collaboration. For more information, visit Bloomberg.com/company or request a demo.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bloomberg-expands-global-equity-offering-with-australia-domestic-equity-indices-302756047.html

    SOURCE Bloomberg L.P.

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $AD

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    7/9/2026$135.00Hold
    Jefferies
    Agilent Technologies Inc.
    $A
    6/26/2026$155.00Outperform
    Bernstein
    Agilent Technologies Inc.
    $A
    6/11/2026$150.00Neutral
    Piper Sandler
    Agilent Technologies Inc.
    $A
    5/28/2026$145.00Neutral → Buy
    BofA Securities
    Agilent Technologies Inc.
    $A
    5/27/2026$153.00Outperform
    RBC Capital Mkts
    Array Digital Infrastructure Inc.
    $AD
    5/12/2026$52.00Outperform → Sector Perform
    RBC Capital Mkts
    Array Digital Infrastructure Inc.
    $AD
    5/11/2026Outperform → Mkt Perform
    Raymond James
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    More analyst ratings

    $A
    $AD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

    Test enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s PD‑1‑targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusi

    7/14/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

    Agilent Technologies Inc. (NYSE:A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody

    7/8/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

    Simplifying label-free imaging analysis for more confident real-time cell analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach i

    7/1/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Agilent with a new price target

    Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00

    7/9/26 8:26:11 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bernstein resumed coverage on Agilent with a new price target

    Bernstein resumed coverage of Agilent with a rating of Outperform and set a new price target of $155.00

    6/26/26 9:17:41 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Piper Sandler initiated coverage on Agilent with a new price target

    Piper Sandler initiated coverage of Agilent with a rating of Neutral and set a new price target of $150.00

    6/11/26 8:10:17 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/29/26 4:03:17 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)

    3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:06:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:03:05 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    SEC Filings

    View All

    Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    6/25/26 4:23:06 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Array Digital Infrastructure Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - ARRAY DIGITAL INFRASTRUCTURE, INC. (0000821130) (Filer)

    6/1/26 4:09:49 PM ET
    $AD
    Telecommunications Equipment
    Telecommunications

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    6/1/26 4:09:02 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Michael Buckner as Chief Legal Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and

    5/4/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Cancer Research Solutions at AACR 2026

    Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla

    4/15/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Array Appoints Anthony Carlson President and CEO

    CHICAGO, Nov. 7, 2025 /PRNewswire/ -- Array Digital Infrastructure, Inc. SM (NYSE:AD) (ArraySM), and Telephone and Data Systems, Inc. (NYSE:TDS) today announced Anthony Carlson will become the President and CEO of Array on November 16, 2025. Concurrently, Anthony Carlson will join the Array Board of Directors. As President and CEO of Array, he will be responsible for overseeing operations and strategic initiatives related to the portfolio of 4,400 owned towers, noncontrolling investment interests in wireless partnerships and retained wireless spectrum. "We are very pleased to have Anthony lead our growing tower business and provide strategic vision to its operations," said Walter Carlson, T

    11/7/25 7:30:00 AM ET
    $AD
    $TDS
    Telecommunications Equipment
    Telecommunications

    $A
    $AD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $AD
    Financials

    Live finance-specific insights

    View All

    Array completes sale of select spectrum assets to Verizon for $1.0 billion

    Board declares special dividend of $11.00 per shareCHICAGO, June 1, 2026 /PRNewswire/ -- Array Digital Infrastructure, Inc. (NYSE:AD) (ArraySM) today announced the successful closing of the previously announced agreement with Verizon (NYSE:VZ) to sell a portion of the Company's retained spectrum licenses for total consideration of $1.0 billion.  Additionally, certain spectrum sales to T-Mobile totaling $168M, primarily related to 700MHz and 600MHz, were completed in May.These transactions further the objective announced on May 28, 2024, to opportunistically monetize remaining spectrum following the sale of the T-Mobile wireless operation which closed on August 1, 2025.Considering the closing

    6/1/26 4:05:00 PM ET
    $AD
    $TDS
    $VZ
    Telecommunications Equipment
    Telecommunications

    Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

    Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre

    5/27/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru

    5/20/26 4:27:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials